A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have added about 7.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited ...

Sage Therapeutics shares last traded at $7.27, with a volume of 1,302,493 shares trading hands. Wall Street Analysts Forecast Growth Several analysts have recently commented on SAGE shares.

Bank of America started coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report released on Tuesday. The brokerage issued an underperform rating and a $5.00 target price on the ...

https://www.tipranks.com/news/the-fly/medtronic-price-target-raised-to-93-from-89-at-truist Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE ...

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Sage Chief Medical Officer Laura Gault, M.D., Ph.D., is stepping down to pursue a new opportunity effective March 21, the ...

In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality ...